Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Drugmaker Eli Lilly has launched a new website specifically for prescribing weight loss drugs through a telehealth service less than a month after the company's new injectable, Zepbound, became available in U.S. pharmacies for overweight or obese adults.

Pharmaceutical First: Eli Lilly Website Will Prescribe Weight Loss Drugs Through Service

Eli Lilly and Co (NYSE:LLY) shares have gained more than 8% during the past five trading sessions on investor enthusiasm over prospects for the company's weight-loss drug Zepbound.  In a client update on Tuesday, BMO analysts noted that Lilly's drug already appeared to be taking market share away from Novo Nordisk's Ozempic and Wegovy.

Eli Lilly stock climbs in 2024 on weight-loss drug outlook

Pfizer

Biotech stocks to watch in the stock market today.

2 Biotech Stocks For Your January 2024 Watchlist

Eli Lilly & Co. LLY, +4.31% on Thursday announced the launch of digital health services for U.S. patients with obesity, migraine and diabetes, saying its new LillyDirect platform will offer access to independent healthcare providers and home delivery of certain Lilly drugs through third-party dispensing services. The platform's online pharmacy will automatically apply savings card discounts for people who qualify and will ship medicines free of charge, Lilly said in a release.

Eli Lilly launches digital health services for patients with obesity, migraine and diabetes

Eli Lilly and Co said on Thursday it does not promote the use of its obesity and diabetes drugs Mounjaro and Zepbound outside of their approved purposes, and said it stands against their use for "cosmetic weight loss".

Lilly says it stands against cosmetic use of its weight-loss drugs

INDIANAPOLIS , Jan. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced LillyDirect™, a new digital healthcare experience for patients in the U.S. living with obesity, migraine and diabetes. LillyDirect offers disease management resources, including access to independent healthcare providers*, tailored support, and direct home delivery of select Lilly medicines through third-party pharmacy dispensing services.

Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect™

Eli Lilly is a major player in the billion-dollar weight loss drug market. Demand for these types of drugs has climbed -- and could continue to soar in the coming years.

Everyone Is Talking About Eli Lilly. Is It a Good Long-Term Option?

After a difficult 2023, biopharma investors won't necessarily have it any easier in 2024, analysts at UBS argued in a note to clients on Tuesday.  “BioPharma investors will be happy to shut the door on a tough 2023,” the analysts wrote, noting that the sector declined more than 5% during the year.

BioPharma stocks face a potentially rocky 2024, analysts say

Early data points to Lilly's weight-loss drug Zepbound taking market share away from Ozempic and Wegovy. However, Novo Nordisk could still top Lilly in sales gains this year.

Why Eli Lilly Stock Is Jumping Today While the Overall Market Is Slumping

Eli Lilly's valuation sets a high bar for the stock. Its rival in the obesity space is a better deal and could be a better business.

Missed Out on Eli Lilly? My Best Pharmaceutical Stock to Buy And Hold

INDIANAPOLIS , Jan. 2, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the 42nd Annual J.P. Morgan Healthcare Conference, Jan. 8-11, 2024.

Lilly to Participate in J.P. Morgan Healthcare Conference

Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimer's. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly.

Eli Lilly (LLY) Stock Up 57% in 2023: Will the Uptrend Continue?

Novo Nordisk

Spending on anti-obesity medication is increasing, with some individuals spending more on medication than on food. Novo Nordisk's semaglutide drug, sold as Wegovy, is in high demand and the company is struggling to meet the soaring demand. Expenditures on obesity drugs may eventually exceed spending on food, becoming an important indicator of a country's wealth and standard of living.

Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly

Advanced Micro Devices

Broadcom

Tesla

Visa

As it stands now, six U.S.-listed stocks are in the “trillion dollar club,” or stocks with a market cap of at least $1 trillion. In the coming year, or in the years ahead, which other mega-cap stocks (stocks with a market cap of $200 billion or more) will join them and become the next trillion-dollar companies?

2024's Power Players: 7 Stocks Racing to a Trillion Valuation

The company's early Alzheimer's treatment, donanemab, may soon obtain approval from regulators. It has the potential to generate billions in revenue and may act as another growth catalyst for Lilly.

Why Eli Lilly Stock Could Start Off 2024 With a Bang

ARM Holdings PLC

Costco

SPDR Gold Trust

NVIDIA

Palantir Technologies

Plug Power

7 Investments To Avoid In 2024

Eli Lilly is building a foundation for a strong position in the obesity treatment market. Squirrels that hibernate are effective at both gaining and shedding weight.

Why Is Eli Lilly Investing Up to $494 Million to Study Squirrel Hibernation?

Soaring sales of diabetes drug Mounjaro made 2023 a great year to own Eli Lilly stock. Peak annual sales of recently-approved weight-management drug Zepbound (which has the same active ingredient as Mounjaro) are expected to exceed $25 billion.

Eli Lilly Stock Jumped 59% in 2023. Is It a Good Stock to Buy in 2024?

Microsoft

Ken Griffin is the founder, CEO and majority owner of Citadel, one of the premier hedge funds. Griffin founded the company in 1990 and grew it into what it is today through a combination of quantitative trading and macro strategies.

3 Ken Griffin Stocks to Invest Like Citadel

CME Group

Johnson & Johnson

Coca-Cola

Lockheed Martin

Novartis

PepsiCo

Procter & Gamble

Roche Holding AG

Raytheon Technologies

SPDR S&P 500 ETF Trust

I review the stocks of five world-class companies that I am convinced will bring me closer to my ambitious goal of being able to fund my living expenses through dividends.

Your New Year's Resolution For 2024: Invest $10,000 In These 5 Stocks

Eli Lilly is the developer of Mounjaro, a diabetes treatment generating billions in sales. Pfizer has had its challenges as it looks to enter the diabetes and obesity markets.

Interested in the Weight-Loss Market? Here's 1 Stock to Buy Hand Over Fist in 2024, and 1 to Avoid Like the Plague.

Point Biopharma Global

INDIANAPOLIS , Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. "Next generation radioligand therapies hold great promise for delivering meaningful advances against a range of cancers and we are excited to enter this space through the addition of POINT," said Jacob Van Naarden, executive vice president and president, Loxo@Lilly.

Lilly Completes Acquisition of POINT Biopharma

Bristol-Myers

Fusion Pharmaceuticals

RayzeBio Inc

Fusion Pharmaceuticals Inc.'s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceuticals “is potentially the sole remaining clinical-stage, targeted radiopharm player with a robust supply chain,” analysts said in a research note on Wednesday.

Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target

Amgen

Things could hardly have gone worse for healthcare investors this year.

Healthcare Stocks Had a Terrible 2023. Things Are Looking Up.

Eli Lilly could earn an important approval in 2024. The company's financial results could improve, too.

News for Eli Lilly Stock (LLY)